- Home
- CKPT vs ASM Comparison
CKPT vs ASM Comparison
Compare CKPT & ASM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- ASM
- Stock Information
- Founded
- CKPT 2014
- ASM 1968
- Country
- CKPT United States
- ASM Canada
- Employees
- CKPT N/A
- ASM N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- ASM Metal Mining
- Sector
- CKPT Health Care
- ASM Basic Materials
- Exchange
- CKPT Nasdaq
- ASM Nasdaq
- Market Cap
- CKPT 151.9M
- ASM 146.2M
- IPO Year
- CKPT 2017
- ASM N/A
- Fundamental
- Price
- CKPT $3.00
- ASM $1.14
- Analyst Decision
- CKPT Strong Buy
- ASM Strong Buy
- Analyst Count
- CKPT 2
- ASM 2
- Target Price
- CKPT $13.50
- ASM $1.80
- AVG Volume (30 Days)
- CKPT 998.1K
- ASM 1.2M
- Earning Date
- CKPT 11-12-2024
- ASM 11-12-2024
- Dividend Yield
- CKPT N/A
- ASM N/A
- EPS Growth
- CKPT N/A
- ASM 144.19
- EPS
- CKPT N/A
- ASM 0.02
- Revenue
- CKPT $47,000.00
- ASM $54,326,000.00
- Revenue This Year
- CKPT N/A
- ASM $40.31
- Revenue Next Year
- CKPT $172,016.02
- ASM $33.83
- P/E Ratio
- CKPT N/A
- ASM $43.41
- Revenue Growth
- CKPT N/A
- ASM 18.08
- 52 Week Low
- CKPT $1.38
- ASM $0.44
- 52 Week High
- CKPT $4.50
- ASM $1.56
- Technical
- Relative Strength Index (RSI)
- CKPT 38.29
- ASM 63.12
- Support Level
- CKPT $3.07
- ASM $1.06
- Resistance Level
- CKPT $3.42
- ASM $1.21
- Average True Range (ATR)
- CKPT 0.21
- ASM 0.06
- MACD
- CKPT -0.03
- ASM 0.03
- Stochastic Oscillator
- CKPT 4.94
- ASM 80.56
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.